Exciting Updates from the Latest Financial Report Developments in Revenue and Partnerships In the third quarter, our total revenue reached an impressive $55.3 million, bolstered by strong sales of TAVALISSE®, REZLIDHIA®, and GAVRETO®. Specifically, TAVALISSE® net product sales contributed $26.3 million, REZLIDHIA® net product sales added $5.5 million, and GAVRETO® net product sales accounted for…
Moderna Inc. Q3 2024 Earnings Conference Call: A Look Into the Future of Biotech Company Overview Moderna Inc. (NASDAQ: MRNA) is a leading biotechnology company that is at the forefront of developing revolutionary mRNA-based therapeutics and vaccines. With a strong leadership team led by Chief Executive Officer Stéphane Bancel and President Stephen Hoge, Moderna has…
Welcome to the Warner Bros. Discovery, Inc. Q3 2024 Earnings Conference Call! About the Participants David Zaslav is the President and Chief Executive Officer of Warner Bros. Discovery, Inc. Gunnar Wiedenfels serves as the Chief Financial Officer. JB Perrette holds the position of CEO and President of Global Streaming and Games. Andrew Slabin is the…
Welcome to Match Group’s Q3 2024 Earnings Conference Call Key Participants Tanny Shelburne – Senior Vice President, Investor Relations Bernard Kim – Chief Executive Officer Gary Swidler – President and Chief Financial Officer Conference Call Participants Ross Sandler – Barclays Benjamin Black – Deutsche Bank Jason Helfstein – Oppenheimer John Blackledge – TD Cowen Nathan…
Welcome to the World of Wall Street Analysts and Price Targets! Have you ever wondered how Wall Street analysts come up with price targets for stocks? Well, it’s a combination of financial analysis, market trends, and a sprinkle of magic fairy dust. Okay, maybe not magic fairy dust, but you get the idea. The average…
Join the Schall Law Firm in Pursuing Justice for Investors: A Securities Fraud Case Against Edwards Lifesciences Corporation Introduction LOS ANGELES, CA / ACCESSWIRE / November 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Edwards Lifesciences Corporation (“Edwards Lifesciences” or “the Company”)…
Welcome to the Catalyst Pharmaceuticals, Inc. Q3 2024 Earnings Conference Call Key Players in the Call Richard Daly, President and Chief Executive Officer of Catalyst Pharmaceuticals, Inc., kicked off the call with an overview of the company’s performance in the third quarter. Michael Kalb, Chief Financial Officer, provided detailed financial results. Jeffrey Del Carmen, Chief…
Immunic Inc (NASDAQ:IMUX) Shows Strong Financial Position Advancing Key Clinical Programs with Over $59 Million in Cash Immunic Inc, a biopharmaceutical company focused on developing oral therapies for chronic inflammatory and autoimmune diseases, has ended the third quarter of 2024 with over $59 million in cash. This strong financial position allows the company to advance…
